trends in biopharma cold chain - flypharmaus.com€¦ · in 2018, cold chain is 18% of total pharma...

14
New products, new channels Nick Basta, Pharmaceutical Commerce TRENDS IN BIOPHARMA COLD CHAIN

Upload: others

Post on 28-Jul-2020

6 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: TRENDS IN BIOPHARMA COLD CHAIN - flypharmaus.com€¦ · In 2018, cold chain is 18% of total pharma spend. Cold chain spend is 71% transport, 29% pkg’g. Air and parcel is the dominant

New products, new channels

Nick Basta, Pharmaceutical Commerce

TRENDS IN BIOPHARMA COLD CHAIN

Page 2: TRENDS IN BIOPHARMA COLD CHAIN - flypharmaus.com€¦ · In 2018, cold chain is 18% of total pharma spend. Cold chain spend is 71% transport, 29% pkg’g. Air and parcel is the dominant

21,000 SUBSCRIBERS; COMMERCIAL OPS, SALES/MARKETING, SUPPLY CHAIN, REGULATORY COMPLIANCE

The flow of products, information and revenue in the global biopharma industry

Page 3: TRENDS IN BIOPHARMA COLD CHAIN - flypharmaus.com€¦ · In 2018, cold chain is 18% of total pharma spend. Cold chain spend is 71% transport, 29% pkg’g. Air and parcel is the dominant

Quarterly magazine; annual Sourcebook

Page 4: TRENDS IN BIOPHARMA COLD CHAIN - flypharmaus.com€¦ · In 2018, cold chain is 18% of total pharma spend. Cold chain spend is 71% transport, 29% pkg’g. Air and parcel is the dominant
Page 5: TRENDS IN BIOPHARMA COLD CHAIN - flypharmaus.com€¦ · In 2018, cold chain is 18% of total pharma spend. Cold chain spend is 71% transport, 29% pkg’g. Air and parcel is the dominant

’Normal’ distribution

Pharmaceutical Supply Chain from a track-and-trace perspective

Packaging

CMOPallets are shippedSKU in cases

Cases on pallets

All uniquely identified

3PLSCarrier

Pallets or individual cases

get pulled or shipped

Cases and SKUs are

scanned & shipped to

customer

Distribution

Pharmacy

Serial number

scan

Gov

Customer

Distributor

Page 6: TRENDS IN BIOPHARMA COLD CHAIN - flypharmaus.com€¦ · In 2018, cold chain is 18% of total pharma spend. Cold chain spend is 71% transport, 29% pkg’g. Air and parcel is the dominant

Multiplying distribution channels

Page 7: TRENDS IN BIOPHARMA COLD CHAIN - flypharmaus.com€¦ · In 2018, cold chain is 18% of total pharma spend. Cold chain spend is 71% transport, 29% pkg’g. Air and parcel is the dominant

On the horizon: personalized cell/gene therapycredit: World Courier

Page 8: TRENDS IN BIOPHARMA COLD CHAIN - flypharmaus.com€¦ · In 2018, cold chain is 18% of total pharma spend. Cold chain spend is 71% transport, 29% pkg’g. Air and parcel is the dominant

Cold chain products have 2X non-cold-chain growth

Page 9: TRENDS IN BIOPHARMA COLD CHAIN - flypharmaus.com€¦ · In 2018, cold chain is 18% of total pharma spend. Cold chain spend is 71% transport, 29% pkg’g. Air and parcel is the dominant

In 2018, cold chain is 18% of total pharma spend

Page 10: TRENDS IN BIOPHARMA COLD CHAIN - flypharmaus.com€¦ · In 2018, cold chain is 18% of total pharma spend. Cold chain spend is 71% transport, 29% pkg’g. Air and parcel is the dominant

Cold chain spend is 71% transport, 29% pkg’g

Page 11: TRENDS IN BIOPHARMA COLD CHAIN - flypharmaus.com€¦ · In 2018, cold chain is 18% of total pharma spend. Cold chain spend is 71% transport, 29% pkg’g. Air and parcel is the dominant

Air and parcel is the dominant mode

Page 12: TRENDS IN BIOPHARMA COLD CHAIN - flypharmaus.com€¦ · In 2018, cold chain is 18% of total pharma spend. Cold chain spend is 71% transport, 29% pkg’g. Air and parcel is the dominant

Europe is the largest services market

Page 13: TRENDS IN BIOPHARMA COLD CHAIN - flypharmaus.com€¦ · In 2018, cold chain is 18% of total pharma spend. Cold chain spend is 71% transport, 29% pkg’g. Air and parcel is the dominant

Clinical trial logistics market is substantial, but slow-growing

Page 14: TRENDS IN BIOPHARMA COLD CHAIN - flypharmaus.com€¦ · In 2018, cold chain is 18% of total pharma spend. Cold chain spend is 71% transport, 29% pkg’g. Air and parcel is the dominant

Trends to watch:

• International movement is mostly pallet-scale, mostly active container; but passive options are multiplying

• CEIV Pharma program is growing in acceptance, but global practices still vary by country

• How much temperature-controlled CRT shipping? 5-15% in the US, higher in Europe with tighter GDP standards

• How fast will cell/gene therapies grow?

• More reuse of cold-chain packaging is in store: “Cold chain as a service”

• More real-time monitoring of temperature AND external parameters is being offered—but who owns the data?